Olivier Biondi
                                    31 
                                    
                            Documents
                                Publications
Publications
        
            Le métabolisme musculaire comme déterminant de l’orientation physiothérapeutique dans le diabète de type 2Thérapies innovantes et combinatoires #2 - "Innovation thérapeutique : Quels enjeux pour le développement des thérapies combinatoires ?", Université d'Evry; Genopole, Jun 2023, Evry, France 
                 Communication dans un congrès
                    
        
        
            
                
                    hal-04495968
                                            v1
                                    
            
        
     | 
|
        
            Combination of antisense oligonucleotide therapy with BIO101 demonstrates synergistic beneficial effects in severe SMA-like mice17th International Congress on Neuromuscular Disease, Jul 2022, Bruxelles (BEL), Belgium 
                 Communication dans un congrès
                    
        
        
            
                
                    hal-04496142
                                            v1
                                    
            
        
     | 
|
        
            Synergistic beneficial effects of BIO101 in combination with antisense oligonucleotide therapy in severe SMA-like mice3èmes International Scientific Congress on SMA, SMA Europe, Oct 2022, Barcelone (ES), Spain 
                 Communication dans un congrès
                    
        
        
            
                
                    hal-04496200
                                            v1
                                    
            
        
     | 
|
        
            Combination of BIO101 with antisense oligonucleotide therapy demonstrates synergistic beneficial effects in severe SMA-like miceMyology 2022, Sep 2022, Nice, France 
                 Communication dans un congrès
                    
        
        
            
                
                    hal-04496181
                                            v1
                                    
            
        
     | 
|
        
            Combination of antisense oligonucleotide therapy with BIO101 demonstrates synergistic beneficial effects in severe SMA-like miceAnnual SMA research & Clinical Care Meeting, Jul 2022, Anaheim (CA), United States 
                 Communication dans un congrès
                    
        
        
            
                
                    hal-04496110
                                            v1
                                    
            
        
     | 
|
        
            Combinatory therapeutic innovation for Spinal Muscular AtrophyInnovative, combinatory therapies for neuromuscular diseases, Genopole; Université d'Evry, May 2022, Evry, France 
                 Communication dans un congrès
                    
        
        
            
                
                    hal-04495948
                                            v1
                                    
            
        
     | 
|
        
            Sarconeos (API BIO101) improves outcomes in a mouse model of severe spinal muscular atrophy18èmes Journées de la Société Française de Myologie, SFM, Nov 2021, Saint-Etienne (FR), France 
                 Communication dans un congrès
                    
        
        
            
                
                    hal-04496219
                                            v1
                                    
            
        
     | 
|
        
            L'intensité de l'effort, un élément clef des effets de l'exercice dans la SMA ?33èmes Entretiens Annuels de la Fondation Garches, Fondation Garches, Nov 2021, Boulogne-Billancourt, France 
                 Communication dans un congrès
                    
        
        
            
                
                    hal-04495959
                                            v1
                                    
            
        
     | 
|
        
            Regular exercise prolongs survival in a type 2 SMA model mouse10th International Spinal Mucular Atrophy research Group Meeting, 10,11,12 juin 2006 Montréal, Canada, 2006, Canada 
                 Communication dans un congrès
                    
        
        
            
                
                    hal-00091129
                                            v1
                                    
            
        
     | 
        
            Exercise-specific effects on the motor performance, glycemia regulation and muscle histology of a mouse model of limb-girdle muscular dystrophy r1 (calpainopathy)20èmes journées de la Société Française de Myologie, Nov 2023, La Baule (France), France.  
                 Poster de conférence
                    
        
        
            
                
                    hal-04496479
                                            v1
                                    
            
        
     | 
|
        
            Exercise-specific effects on the motor performance, glycemia regulation and muscle histology of a mouse model of limb-girdle muscular dystrophy r1 (calpainopathy)28th annual congress of European College of Sport Science, Jul 2023, Paris, France.  
                 Poster de conférence
                    
        
        
            
                
                    hal-04496489
                                            v1
                                    
            
        
     | 
|
        
            In vivo effects of Sarconeos (API BIO101) on a mouse model of severe spinal muscular atrophyWorld Muscle Society 2021 Virtual Congress, Sep 2021, Paris, France.  
                 Poster de conférence
                    
        
        
            
                
                    hal-04496236
                                            v1
                                    
            
        
     | 
        
            Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseasesFrance, Patent n° : EP3937948A1. 2022 
                 Brevet
                    
        
        
            
                
                    hal-04496584
                                            v1
                                    
            
        
     | 
|
        
            ERK inhibitors for use in treating spinal muscular atrophyFrance, Patent n° : 61/489,721. 2011 
                 Brevet
                    
        
        
            
                
                    hal-04496509
                                            v1
                                    
            
        
     | 
                Chargement...
            
            Chargement...